Atezolizumab in the treatment of small cell lung cancer
Small cell lung cancer (SCLC) remains one of the most aggressive cancers, with a high relapse rate and limited treatment outcomes. The introduction of immunotherapy, including PD-L1 inhibitors such as atezolizumab and durvalumab, has changed the standard of care, especially in advanced-stage diseas...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-06-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/60497 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|